B7-H3 Antibody-Drug Conjugates Gain Momentum as Frontline Standards Shift Across Solid Tumors
B7-H3 Antibody-Drug Conjugates Gain Momentum as Frontline Standards Shift Across Solid Tumors
Lonza Expands ADC Capabilities with Strategic Investments and Integrated Technologies
Lonza Expands ADC Capabilities with Strategic Investments and Integrated Technologies
Novartis and Myricx Bio: Pioneering Next-Generation ADC Innovation with N-Myristoyltransferase Inhibitor Payloads
Novartis and Myricx Bio: Pioneering Next-Generation ADC Innovation with N-Myristoyltransferase Inhibitor Payloads
Practice-Changing Advances in Early HER2-Positive Breast Cancer: ASCO 2026 and FDA Approvals Establish Trastuzumab...
Practice-Changing Advances in Early HER2-Positive Breast Cancer: ASCO 2026 and FDA Approvals Establish Trastuzumab Deruxtecan as a New Standard
Sigvotatug Vedotin in Previously Treated Metastatic Non-Squamous Non-Small Cell Lung Cancer: Topline Results from...
Sigvotatug Vedotin in Previously Treated Metastatic Non-Squamous Non-Small Cell Lung Cancer: Topline Results from the Phase 3 SigVie-002 Study
Advancing Next-Generation Radiopharmaceuticals through Regio-Selective Conjugation
Advancing Next-Generation Radiopharmaceuticals through Regio-Selective Conjugation
AmMax Bio Licenses Antibody-Drug Conjugate Technology for Hematological Cancers from Lonza
AmMax Bio, a private clinical-stage biopharmaceutical company developing an innovative portfolio of antibody-drug conjugates (ADC) in oncology, and Lonza, the world’s leading contract development...
TLX591-Tx in Combination With Standard-of-Care in Metastatic Castration-Resistant Prostate Cancer: Results From Part 1...
TLX591-Tx in Combination With Standard-of-Care in Metastatic Castration-Resistant Prostate Cancer: Results From Part 1 of the Phase 3 ProstACT Global Study
Advances, Sequencing Challenges, and Real-World Integration of ADCs in Breast Cancer: Insights from ASCO...
Advances, Sequencing Challenges, and Real-World Integration of ADCs in Breast Cancer: Insights from ASCO 2026
FDA Approves Pivekimab Sunirine as First Outpatient ADC for the Treatment of Ultra-Rare Hematologic...
In a landmark advancement for patients with ultra-rare blood cancers, the U.S. Food and Drug Administration (FDA) has approved pivekimab sunirine (Decnupaz™; AbbVie), previously known as IMGN632, marking the first and only antibody-drug conjugate (ADC) authorized for the treatment of adult patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN).
